LRRK2 Rabbit mAb

活动价:

¥880.00

市场价:¥1280.00

一键复制产品信息
产品规格:
  • 50μL
货号:

FAB2622082

  • 产品信息
  • 注意事项
  • 实验验证
  • 产品声明
  • 引用文献
  • 相关产品
  • 文件下载
商品描述
  • 靶点-Target

    LRRK2

  • 反应性

    Human,Mouse,Rat

  • 应用

    WB,IHC,IF,IP,ELISA

  • 宿主物种-Host Species

    Rabbit

  • 同种型-Isotype

    IgG,Kappa

  • MW(Calculated)

    286kD

  • MW(Observed)

    286kD

  • 推荐稀释比

    IHC 1:500-1:1000;WB 1:2000-1:10000;IF 1:200-1:1000;ELISA 1:5000-1:20000;IP 1:50-1:200;

  • 组成

    PBS, 50% glycerol, 0.05% Proclin 300, 0.05%BSA

  • 纯化工艺

    Protein A

  • 储存

    -15°C to -25°C/1 year(Do not lower than -25°C)

  • 克隆性

    Monoclonal

  • 克隆号

    PT0940R

  • 特异性

    Endogenous

  • 基因名称

    LRRK2 PARK8

  • 蛋白名称

    Leucine-rich repeat serine/threonine-protein kinase 2 (Dardarin)

  • Organism-1

    Human

  • 基因ID-1

    120892

  • SwissProt-1

    Q5S007

  • Organism-2

    Mouse

  • SwissProt-2

    Q5S006

  • 背景

    This gene is a member of the leucine-rich repeat kinase family and encodes a protein with an ankryin repeat region, a leucine-rich repeat (LRR) domain, a kinase domain, a DFG-like motif, a RAS domain, a GTPase domain, a MLK-like domain, and a WD40 domain. The protein is present largely in the cytoplasm but also associates with the mitochondrial outer membrane. Mutations in this gene have been associated with Parkinson disease-8. [provided by RefSeq, Jul 2008],

  • 细胞定位

    Catalytic activity:ATP + a protein = ADP + a phosphoprotein.,Disease:Defects in LRRK2 are the cause of Parkinson disease 8 (PARK8) [MIM:607060, 168600]. Parkinson disease (PD) is a complex, multifactorial disorder that typically manifests after the age of 50 years, although early-onset cases (before 50 years) are known. PD generally arises as a sporadic condition but is occasionally inherited as a simple mendelian trait. Although sporadic and familial PD are very similar, inherited forms of the disease usually begin at earlier ages and are associated with atypical clinical features. PD is characterized by bradykinesia, resting tremor, muscular rigidity and postural instability, as well as by a clinically significant response to treatment with levodopa. The pathology involves the loss of dopaminergic neurons in the substantia nigra and the presence of Lewy bodies (intraneuronal accumulations of aggregated proteins), in surviving neurons in various areas of the brain. PARK8 is an autosomal-dominant late-onset parkinsonism, characterized by onset from 50 to 65 years, with slow progression and relatively benign course.,Function:Probable protein kinase whose role is not yet known. May play a role in the phosphorylation of proteins central to Parkinson disease. May also have GTPase activity.,similarity:Belongs to the protein kinase superfamily.,similarity:Belongs to the protein kinase superfamily. TKL Ser/Thr protein kinase family.,similarity:Contains 1 protein kinase domain.,similarity:Contains 1 Roc domain.,similarity:Contains 16 LRR (leucine-rich) repeats.,subcellular location:Localized in the cytoplasm and associated with cellular membrane structures. Associates with the mitochondrial outer membrane.,subunit:Interacts with PARK2.,tissue specificity:Expressed throughout the adult brain, but at a lower level than in heart and liver. Also expressed in placenta, lung, skeletal muscle, kidney and pancreas. In the brain, expressed in the cerebellum, cerebral cortex, medulla, spinal cord occipital pole, frontal lobe, temporal lobe and putamen. Expression is particularly high in brain dopaminoceptive areas.,